{"id":847939,"date":"2025-05-07T07:08:31","date_gmt":"2025-05-07T11:08:31","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/castle-biosciences-celebrates-skin-cancer-awareness-month-2\/"},"modified":"2025-05-07T07:08:31","modified_gmt":"2025-05-07T11:08:31","slug":"castle-biosciences-celebrates-skin-cancer-awareness-month-2","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/castle-biosciences-celebrates-skin-cancer-awareness-month-2\/","title":{"rendered":"Castle Biosciences Celebrates Skin Cancer Awareness Month"},"content":{"rendered":"
\n

\n The Company continues its ongoing partnerships with IMPACT Melanoma, AIM at Melanoma and Melanoma Research Foundation to drive education and awareness throughout May<\/em>\n <\/p>\n

\n Castle highlights cancer journey of melanoma survivor and advocate, Leah Adams<\/em>\n <\/p>\n

\n Castle Biosciences Celebrates Skin Cancer Awareness Month: Castle Biosciences Celebrates Skin Cancer Awareness Month<\/a>\n <\/p>\n

\u00a0A Media Snippet accompanying this announcement is available in this link.<\/a><\/p>\n

FRIENDSWOOD, Texas, May 07, 2025 (GLOBE NEWSWIRE) — Castle Biosciences, Inc.\u00a0(Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, is recognizing Skin Cancer Awareness Month this May by supporting a series of initiatives designed to raise awareness, educate patients and families and empower those impacted by skin cancer.<\/p>\n

\u201cAt Castle, our mission is rooted in delivering clinically actionable information to patients and their clinical care teams \u2014 and that begins with awareness and education,\u201d said Derek Maetzold, president and chief executive officer of Castle Biosciences. \u201cBy supporting organizations like IMPACT Melanoma and sharing real patient stories like Leah\u2019s, we aim to drive conversations around early detection and personalized risk assessment in an effort to help improve patient outcomes.\u201d<\/p>\n

\n Empowering Patients and Caregivers: IMPACT Melanoma Virtual Patient Symposium<\/strong>
\n
Castle is proud to continue its long-standing partnership with IMPACT Melanoma by sponsoring the organization\u2019s upcoming virtual patient symposium, \u201cMelanoma Diagnosis: A Toolkit to Support the Journey.\u201d<\/em> The event will be held on Wednesday, May 21, 2025, at 6 p.m. ET<\/strong>, and has been designed to provide individuals newly diagnosed with melanoma \u2014 and their support networks \u2014 with practical tools, resources and compassionate guidance to navigate the melanoma journey.<\/p>\n

Aaron Farberg, M.D., FAAD, double board-certified dermatologist, Mohs surgeon and chief medical officer of Bare Dermatology in Dallas, will lead the discussion, joined by dermatology interest group students Mitchell Hanson and Brianna Speigel. Topics will include navigating a diagnosis, emotional support resources, survivorship planning and how patients and caregivers can more effectively advocate for melanoma care. Registration details can be found here<\/a>.<\/p>\n

\u201cThis symposium was created to meet people where they are \u2014 at a vulnerable moment in their lives,\u201d said Deb Girard, executive director of IMPACT Melanoma. \u201cWe want everyone who attends, whether they are just beginning their journey or supporting someone who is, to walk away feeling more informed, supported and empowered.\u201d<\/p>\n

\n Leah\u2019s Story: Living Confidently with the Support of DecisionDx\u00ae-Melanoma<\/strong>
\n
Improving patient care is at the heart of Castle\u2019s mission. This month, Castle is sharing the powerful story of Leah Adams, a melanoma survivor who used Castle\u2019s DecisionDx-Melanoma test to better understand her predicted risk of recurrence. \u201cPeople don\u2019t understand how serious melanoma is,\u201d said Adams. \u201cThe DecisionDx-Melanoma test allows you to really see your risk of recurrence \u2014 whether it\u2019s high- or low-risk \u2014 so you can do everything possible to protect your largest organ. Having the reassurance of the low-risk result helps me move forward and be able to show up for my family and for myself.\u201d<\/p>\n

Leah\u2019s full story can be viewed here<\/a>.<\/p>\n

\n Walking Together Toward a Cure: Castle Rallies for Melanoma Awareness Across the Nation<\/strong>
\n
As part of its commitment to advancing skin cancer awareness, Castle is proud to continue its support of AIM at Melanoma and the Melanoma Research Foundation by participating in multiple advocacy walks throughout the month of May. Taking place across the country, these events bring together survivors, caregivers, clinicians and advocates to raise critical funds for research, education and outreach \u2014 united by a shared goal of finding a cure.<\/p>\n

\n Raising National Awareness: USA TODAY 2025 Skin Health Campaign<\/strong>
\n
Castle is also participating in the 2025 Skin Health Campaign by USA TODAY. The Company is collaborating on an article titled \u201cTransforming Skin Cancer and Melanoma Outcomes,\u201d<\/em> which will appear in the May 30 print edition of USA TODAY and in the digital campaign on usatoday.com<\/a> and Future of Personal Health<\/a>. The article features Shannon Trotter, D.O., FAAD, board-certified dermatologist and host of the Derm-it Trotter! Don\u2019t Swear About Skincare<\/em> podcast, and melanoma advocate Leah Adams, and highlights the growing role of diagnostic testing in guiding personalized care decisions for individuals diagnosed with melanoma.<\/p>\n

More information about Castle\u2019s tests for patients with skin cancer can be found at www.CastleBiosciences.com<\/a>.<\/p>\n

\n About IMPACT Melanoma<\/strong>
\n
IMPACT Melanoma, a national non-profit 501(c)(3) organization, is the nation\u2019s leading non-profit dedicated to significantly reducing melanoma in the United States and saving lives. The focus is on prevention education programs that include customized and integrated programs for communities. In addition to skin cancer prevention education and programs, the organization is committed to supporting melanoma patients and their families and advocating for and influencing urban development policies to address shade equity in America. To learn more about IMPACT Melanoma, visit\u00a0https:\/\/impactmelanoma.org\/<\/a>.<\/p>\n

\n About AIM at Melanoma<\/strong>
\n
Founded in 2004, AIM at Melanoma is a global foundation dedicated to finding more effective treatments and, ultimately, the cure for melanoma. By directing and funding paradigm-shifting research initiatives \u2014 educating patients, healthcare professionals, and the public \u2014 and advocating for survivors and their families, AIM at\u00a0Melanoma\u2019s goal is to end this disease in our lifetime while improving the lives of those it affects. AIM at Melanoma is dedicated to innovation in melanoma research, information and support, and legislation, policy and advocacy. For more information, visit AIMatMelanoma.org<\/a>.<\/p>\n

\n About Melanoma Research Foundation<\/strong>
\n
The Melanoma Research Foundation (MRF) is a 501(c)(3) non-profit organization and the largest independent organization devoted to melanoma. Committed to the support of medical research to develop effective treatments and eventually a cure for melanoma, the MRF also educates patients and physicians about the prevention, diagnosis and treatment of cutaneous melanoma and the melanoma rare subtypes. The MRF is a dedicated advocate for the melanoma community, helping to raise awareness of this disease and the need for a cure. To learn more about the MRF, visit https:\/\/melanoma.org\/<\/a>.<\/p>\n

\n About DecisionDx-Melanoma<\/strong>
\n
DecisionDx-Melanoma is a 31-gene expression profile risk stratification test. It is designed to inform two clinical questions in the management of cutaneous melanoma: a patient\u2019s individual risk of sentinel lymph node (SLN) positivity and a patient’s personal risk of melanoma recurrence and\/or metastasis. By integrating tumor biology with clinical and pathologic factors using a validated proprietary algorithm, DecisionDx-Melanoma is designed to provide a comprehensive and clinically actionable result to guide risk-aligned patient care. DecisionDx-Melanoma has been shown to be associated with improved patient survival and has been studied in more than 10,000 patient samples. DecisionDx-Melanoma\u2019s clinical value is supported by more than 50 peer-reviewed and published studies, providing confidence in disease management plans that incorporate the test\u2019s results. Through March 31, 2025, DecisionDx-Melanoma has been ordered more than 200,000 times for patients diagnosed with cutaneous melanoma. More information about the test and disease can be found at https:\/\/CastleBiosciences.com\/<\/a>.<\/p>\n

\n About Castle Biosciences<\/strong>
\n
Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors.<\/p>\n

Castle\u2019s current portfolio consists of tests for skin cancers, Barrett\u2019s esophagus and uveal melanoma.\u00a0Additionally, the Company has active research and development programs for tests in these and other diseases with high clinical need, including its test in development to help guide systemic therapy selection for patients with moderate-to-severe atopic dermatitis seeking biologic treatment. To learn more, please visit\u00a0www.CastleBiosciences.com<\/a> and connect with us on\u00a0LinkedIn<\/a>,\u00a0Facebook<\/a>,\u00a0X<\/a> and\u00a0Instagram<\/a>.\u202f<\/p>\n

DecisionDx-Melanoma, DecisionDx-CMSeq<\/em>, i31-SLNB, i31-ROR, DecisionDx-SCC, MyPath Melanoma, TissueCypher, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq<\/em> are trademarks of Castle Biosciences, Inc.<\/p>\n

\n Forward-Looking Statements<\/strong>
\n
\n This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the \u201csafe harbor\u201d created by those sections. These forward-looking statements include, but are not limited to, statements concerning: Castle\u2019s ability to (i) raise awareness, educate patients and families and empower those impacted by skin cancer and (ii) deliver actionable information to patients and their clinical care teams; and DecisionDx-Melanoma\u2019s ability to (i) provide comprehensive, personalized results to guide risk-aligned management decisions for patients with stage I-III cutaneous melanoma and (ii) help clinicians make more informed, more precise treatment decisions. The words \u201cbelieve,\u201d \u201ccan,\u201d \u201ccould,\u201d \u201cpotential\u201d and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that we make. These forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from those in the forward-looking statements, including, without limitation: subsequent study or trial results and findings may contradict earlier study or trial results and findings or may not support the results obtained in these studies, including with respect to the discussion of our tests in this press release; actual application of our tests may not provide the aforementioned benefits to patients; and the risks set forth under the heading \u201cRisk Factors\u201d in our Annual Report on Form 10-K for the year ended December 31, 2024 and our Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, each filed or to be filed with the SEC, and in our other filings with the SEC. The forward-looking statements are applicable only as of the date on which they are made, and we do not assume any obligation to update any forward-looking statements, except as may be required by law.<\/em>\n <\/p>\n

\n Investor Contact:<\/strong>
\n
Camilla Zuckero
czuckero@castlebiosciences.com<\/a><\/p>\n

\n Media Contact:<\/strong>
\n
Allison Marshall
amarshall@castlebiosciences.com<\/a><\/p>\n

\n Source: <\/strong>Castle Biosciences Inc.<\/p>\n

A video accompanying this announcement is available at\u00a0<\/p>\n

\n https:\/\/www.globenewswire.com\/NewsRoom\/AttachmentNg\/c6e1c2a7-5df4-42dc-9cbe-bf5f94dce809<\/a>\n <\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

The Company continues its ongoing partnerships with IMPACT Melanoma, AIM at Melanoma and Melanoma Research Foundation to drive education and awareness throughout May Castle highlights cancer journey of melanoma survivor and advocate, Leah Adams Castle Biosciences Celebrates Skin Cancer Awareness Month: Castle Biosciences Celebrates Skin Cancer Awareness Month \u00a0A Media Snippet accompanying this announcement is available in this link. FRIENDSWOOD, Texas, May 07, 2025 (GLOBE NEWSWIRE) — Castle Biosciences, Inc.\u00a0(Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, is recognizing Skin Cancer Awareness Month this May by supporting a series of initiatives designed to raise awareness, educate patients and families and empower those impacted by skin cancer. \u201cAt Castle, our mission is rooted in delivering clinically … <\/p>\n

Continue reading “Castle Biosciences Celebrates Skin Cancer Awareness Month”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-847939","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nCastle Biosciences Celebrates Skin Cancer Awareness Month - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/castle-biosciences-celebrates-skin-cancer-awareness-month-2\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Castle Biosciences Celebrates Skin Cancer Awareness Month - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"The Company continues its ongoing partnerships with IMPACT Melanoma, AIM at Melanoma and Melanoma Research Foundation to drive education and awareness throughout May Castle highlights cancer journey of melanoma survivor and advocate, Leah Adams Castle Biosciences Celebrates Skin Cancer Awareness Month: Castle Biosciences Celebrates Skin Cancer Awareness Month \u00a0A Media Snippet accompanying this announcement is available in this link. FRIENDSWOOD, Texas, May 07, 2025 (GLOBE NEWSWIRE) — Castle Biosciences, Inc.\u00a0(Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, is recognizing Skin Cancer Awareness Month this May by supporting a series of initiatives designed to raise awareness, educate patients and families and empower those impacted by skin cancer. \u201cAt Castle, our mission is rooted in delivering clinically … Continue reading "Castle Biosciences Celebrates Skin Cancer Awareness Month"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/castle-biosciences-celebrates-skin-cancer-awareness-month-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-07T11:08:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ0NTkyMCM2OTI1MzUyIzIwOTYwNzQ=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"8 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/castle-biosciences-celebrates-skin-cancer-awareness-month-2\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/castle-biosciences-celebrates-skin-cancer-awareness-month-2\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Castle Biosciences Celebrates Skin Cancer Awareness Month\",\"datePublished\":\"2025-05-07T11:08:31+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/castle-biosciences-celebrates-skin-cancer-awareness-month-2\\\/\"},\"wordCount\":1646,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/castle-biosciences-celebrates-skin-cancer-awareness-month-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ0NTkyMCM2OTI1MzUyIzIwOTYwNzQ=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/castle-biosciences-celebrates-skin-cancer-awareness-month-2\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/castle-biosciences-celebrates-skin-cancer-awareness-month-2\\\/\",\"name\":\"Castle Biosciences Celebrates Skin Cancer Awareness Month - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/castle-biosciences-celebrates-skin-cancer-awareness-month-2\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/castle-biosciences-celebrates-skin-cancer-awareness-month-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ0NTkyMCM2OTI1MzUyIzIwOTYwNzQ=\",\"datePublished\":\"2025-05-07T11:08:31+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/castle-biosciences-celebrates-skin-cancer-awareness-month-2\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/castle-biosciences-celebrates-skin-cancer-awareness-month-2\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/castle-biosciences-celebrates-skin-cancer-awareness-month-2\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ0NTkyMCM2OTI1MzUyIzIwOTYwNzQ=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ0NTkyMCM2OTI1MzUyIzIwOTYwNzQ=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/castle-biosciences-celebrates-skin-cancer-awareness-month-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Castle Biosciences Celebrates Skin Cancer Awareness Month\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Castle Biosciences Celebrates Skin Cancer Awareness Month - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/castle-biosciences-celebrates-skin-cancer-awareness-month-2\/","og_locale":"en_US","og_type":"article","og_title":"Castle Biosciences Celebrates Skin Cancer Awareness Month - Market Newsdesk","og_description":"The Company continues its ongoing partnerships with IMPACT Melanoma, AIM at Melanoma and Melanoma Research Foundation to drive education and awareness throughout May Castle highlights cancer journey of melanoma survivor and advocate, Leah Adams Castle Biosciences Celebrates Skin Cancer Awareness Month: Castle Biosciences Celebrates Skin Cancer Awareness Month \u00a0A Media Snippet accompanying this announcement is available in this link. FRIENDSWOOD, Texas, May 07, 2025 (GLOBE NEWSWIRE) — Castle Biosciences, Inc.\u00a0(Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, is recognizing Skin Cancer Awareness Month this May by supporting a series of initiatives designed to raise awareness, educate patients and families and empower those impacted by skin cancer. \u201cAt Castle, our mission is rooted in delivering clinically … Continue reading \"Castle Biosciences Celebrates Skin Cancer Awareness Month\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/castle-biosciences-celebrates-skin-cancer-awareness-month-2\/","og_site_name":"Market Newsdesk","article_published_time":"2025-05-07T11:08:31+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ0NTkyMCM2OTI1MzUyIzIwOTYwNzQ=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/castle-biosciences-celebrates-skin-cancer-awareness-month-2\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/castle-biosciences-celebrates-skin-cancer-awareness-month-2\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Castle Biosciences Celebrates Skin Cancer Awareness Month","datePublished":"2025-05-07T11:08:31+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/castle-biosciences-celebrates-skin-cancer-awareness-month-2\/"},"wordCount":1646,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/castle-biosciences-celebrates-skin-cancer-awareness-month-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ0NTkyMCM2OTI1MzUyIzIwOTYwNzQ=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/castle-biosciences-celebrates-skin-cancer-awareness-month-2\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/castle-biosciences-celebrates-skin-cancer-awareness-month-2\/","name":"Castle Biosciences Celebrates Skin Cancer Awareness Month - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/castle-biosciences-celebrates-skin-cancer-awareness-month-2\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/castle-biosciences-celebrates-skin-cancer-awareness-month-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ0NTkyMCM2OTI1MzUyIzIwOTYwNzQ=","datePublished":"2025-05-07T11:08:31+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/castle-biosciences-celebrates-skin-cancer-awareness-month-2\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/castle-biosciences-celebrates-skin-cancer-awareness-month-2\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/castle-biosciences-celebrates-skin-cancer-awareness-month-2\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ0NTkyMCM2OTI1MzUyIzIwOTYwNzQ=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ0NTkyMCM2OTI1MzUyIzIwOTYwNzQ="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/castle-biosciences-celebrates-skin-cancer-awareness-month-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Castle Biosciences Celebrates Skin Cancer Awareness Month"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/847939","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=847939"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/847939\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=847939"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=847939"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=847939"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}